Clinical trials · Pennsylvania
Alzheimer’s disease clinical trials in Pennsylvania
We’re tracking 29 recruiting alzheimer’s disease studies with a site in Pennsylvania — including Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Philadelphia, PennsylvaniaAges 55–80 - NCT05010603Recruiting
Studies families to understand late-onset Alzheimer’s
This study focuses on people with late-onset Alzheimer’s (and some similar memory diseases) and uses a close family “informant” to share what they’ve noticed. It may help researchers learn more about these conditions and how they progress in families.
Pittsburgh, PennsylvaniaAges 55 years+ - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07170150RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
Plymouth Meeting, PennsylvaniaAges 50–90 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Plymouth Meeting, PennsylvaniaAges 50–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Abington, PennsylvaniaAges 60–85 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Philadelphia, PennsylvaniaAges 55–90 - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Philadelphia, PennsylvaniaAges 60–90 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Willow Grove, PennsylvaniaAges 50–85 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Abington, PennsylvaniaAges 55–95 - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Plymouth Meeting, PennsylvaniaAges 60–85 - NCT06245031Enrolling by invitation
Long-term follow-up of sensory stimulation for Alzheimer's
This is a follow-up study for people who already completed the 12-month Hope Study (CA-0011). It tests long-term safety and effects of a gentle sensory stimulation device (light and sound) for Alzheimer's disease. You will continue using the device at home with a study partner.
Jenkintown, PennsylvaniaAges 50–92 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Plymouth Meeting, PennsylvaniaAges 50–85 - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Philadelphia, PennsylvaniaAges 55–90 - NCT05511363RecruitingPhase 3
Study of a new medicine for psychosis in Alzheimer's disease
This trial tests a new drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. If you or a loved one has Alzheimer's and experiences these symptoms, this study might offer a new treatment option.
Allentown, PennsylvaniaAges 55–90 - NCT06126224RecruitingPhase 3
Testing KarXT for Alzheimer's-related psychosis
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
Malvern, PennsylvaniaAges 55–90 - NCT06194799Enrolling by invitationPhase 3
Long-term ACP-204 for Alzheimer's psychosis
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
Abington, PennsylvaniaAges 55–95 - NCT06377033Recruiting
Using health records to advance genomic medicine for all
This study uses electronic health records to learn how to improve genomic medicine across a diverse health system. It may help make DNA-based healthcare more accessible and effective for people with certain conditions.
Philadelphia, PennsylvaniaAges 18 years+ - NCT00869817Recruiting
Study for adults at risk of inherited Alzheimer’s
This study follows people who are at risk for a specific inherited form of Alzheimer’s disease (because a parent has it). It helps researchers learn how the disease starts and changes over time, especially in people who still feel cognitively normal.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06147999Recruiting
Biophoton therapy for brain disorders
This trial tests a biophoton therapy, a light-based treatment, for people with brain disorders. It aims to see if this non-invasive approach can help improve symptoms.
Butler, PennsylvaniaAges 18 years+ - NCT05456503RecruitingPhase 3
PET scan study of tau buildup in memory and brain disorders
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07216716Recruiting
Health app recommendation tool for Alzheimer's caregivers
This study tests a tool that helps find health apps for people caring for a loved one with Alzheimer's or a related dementia. It aims to see if the tool makes it easier to choose useful apps for your caregiving journey.
Pittsburgh, PennsylvaniaAges 18–65 - NCT04165109Recruiting
Down syndrome study to test memory and thinking changes
This study enrolls adults with Down syndrome to better understand how thinking and memory develop and change over time. It may help by building a “trial-ready” group and by measuring thinking in a careful, consistent way.
Pittsburgh, PennsylvaniaAges 25–55
Alzheimer’s disease trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- University of Pittsburgh · 8 studies
- Flourish Research · 3 studies
- University of Pennsylvania · 3 studies
- Abington Neurological Associates · 2 studies
- Abington Neurological Associates Ltd
- Flourish Research - Philadelphia
- Keystone Clinical Studies
- Local Institution - 0004
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Alzheimer’s disease trials in other states
Common questions
- Are there alzheimer’s disease clinical trials in Pennsylvania?
- Yes. We're currently tracking 29 recruiting alzheimer’s disease studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.